We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Avon Products (AVP) Q1 Loss In Line, Revenue Beat Estimates
Avon Products, Inc. , the leading manufacturer and marketer of beauty and related products, reported first-quarter 2018 results. The company posted adjusted loss per share of 2 cents that came in line with the Zacks Consensus Estimate. Further, the company recorded a loss of 7 cents per share in the year-ago quarter.
Earnings Estimate Revision: The Zacks Consensus Estimate for 2018 has been stable in the last 30 days. However, if we look at Avon’s performance in the trailing four quarters (excluding the quarter under review), the company has underperformed the earnings estimates by an average of 35.7%.
Avon Products, Inc. Price, Consensus and EPS Surprise
Avon Products, Inc. Price, Consensus and EPS Surprise | Avon Products, Inc. Quote
Revenues: Avon’s total revenues of $1,393.5 million grew 5% from the year-ago quarter’s figure and also surpassed the Zacks Consensus Estimate of $1,365 million. Further, on a constant dollar basis, revenues rose 2%.
Zacks Rank: Currently, Avon Products carries a Zacks Rank #3 (Hold), which is subject to change following the earnings announcement. You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on Avon Products’ earnings report!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>